Copyright
©The Author(s) 2023.
World J Diabetes. Apr 15, 2023; 14(4): 396-411
Published online Apr 15, 2023. doi: 10.4239/wjd.v14.i4.396
Published online Apr 15, 2023. doi: 10.4239/wjd.v14.i4.396
Table 1 The benefits of different glucagon-like peptide-1 agonist molecules in the management of diabesity based on recent landmark clinical trials[103]
| Drug molecule | Mean weight reduction in kg (95%CI) | Mean % HbA1c reduction (95%CI) | Follow-up period (yr) |
| Exenatide (weekly) | -1.27 (-1.4 to -1.13) | -0.53 (-0.57 to -0.50) | 3.2 |
| Liraglutide | -2.3 (-2.5 to -2.0) | -0.40 (-0.45 to -0.34) | 3.8 |
| Lixisenatide | -0.7 (-0.9 to -0.5) | -0.27 (-0.31 to -0.22) | 2.1 |
| Albiglutide | -0.83 (-1.06 to -0.60) | -0.52 (-0.58 to -0.45) | 1.5 |
| Dulaglutide | -1.46 (-1.67 to -1.25) | -0.61 (-0.65 to -0.58) | 5.4 |
| Semaglutide | -2.87 (-3.47 to –2.28) for 0.5 mg | -0.66 (-0.80 to – 0.52) for 0.5 mg | 2.0 |
| -4.5 (-4.94 to -3.75) for 1 mg | -1.05 (-1.19 to -0.91) for 1 mg |
- Citation: Michaelidou M, Pappachan JM, Jeeyavudeen MS. Management of diabesity: Current concepts. World J Diabetes 2023; 14(4): 396-411
- URL: https://www.wjgnet.com/1948-9358/full/v14/i4/396.htm
- DOI: https://dx.doi.org/10.4239/wjd.v14.i4.396